Brussels, 11/03/2005 (Agence Europe) - 2005 is the year when an initial assessment will be made of the functioning of EU legislation on orphan medicines, after five years of existence. In a press release, Emerging Biopharmaceutical Enterprises points out that 20 new treatments have been provided to patients suffering from rare diseases since the appearance of the regulation. In a White Paper, the association of biotech laboratories calls for additional measures like: - creating a European...